幽门螺杆菌(Helicobacter pylori)是一种人体常见的致病菌,益生菌及其产物已经被认为具有缓解H.pylori感染的作用,该研究旨在评价卷曲乳杆菌CCFM1118制备的后生元1118-Inactivated Bacteria(CCFM1118-IB)对H.pylori感染的缓解作用。该研究通过抑菌实验、细胞黏附实验及菌株共聚集实验分析了CCFM1118-IB对H.pylori生长、定殖的影响;同时使用CCFM1118-IB治疗55名H.pylori感染者,并通过测定感染者13C-尿素呼气值、血清胃蛋白酶原(pepsinogen,PG)浓度、血清生化指标及肠道菌群的组成和丰度等指标以分析CCFM1118-IB对H.pylori感染的缓解作用。实验结果表明,CCFM1118-IB可产生(12.25±0.29) mm的抑菌圈,且对H.pylori具有共聚集作用。同时临床测评显示,CCFM1118-IB可显著降低患者的13C-尿素呼气值、抑制患者PGⅠ/PⅡ升高,并影响患者拟杆菌属、瘤胃球菌等肠道菌的丰度,但CCFM1118-IB并不会影响受试者的正常生理状态。该研究表明,CCFM1118-IB具有抗H.pylori的特性并可以减少H.pylori感染对人类健康的有害影响。
Helicobacter pylori (H.pylori) is a common pathogenic bacterium in humans, which is widely spread in the world.It is a pathogen with potential health hazards associated with a variety of diseases, especially digestive diseases such as chronic gastritis and stomach cancer.Antibiotics are commonly used to treat H.pylori infection, but this has many side effects.In recent years, probiotics and their products have been used for the treatment of H.pylori infection due to their safety, low side effects, and effective elimination.This study aimed to evaluate the alleviating effect of postbiotic element CCFM1118- Inactivated Bacteria (CCFM1118-IB) prepared from Lactobacillus crispatus CCFM1118 on H.pylori infection.The effect of CCFM1118-IB on H.pylori growth and colonization was evaluated using the antibacterial experiment, cell adhesion assay, and strain coaggregation assay.Meanwhile, 55 patients with H.pylori infection were treated with CCFM1118-IB at a dose of 2 g twice daily for one month.13C-urea breath test, serum biochemical parameters, serum pepsinogen concentrations, serum cytokine concentrations, and the gut microbiota of patients were measured at baseline and end-of-trial to analyze the effect of CCFM1118-IB in eradicating H.pylori infection in patients. In vitro study results showed that CCFM1118-IB formed an inhibition circle with (12.25±0.29) mm and had a co-aggregating effect with H.pylori, but it was unable to inhibit the adhesion of H.pylori to cells.In the clinical trial, CCFM1118-IB significantly reduced the 13C-Urea breath test value, inhibited the elevation of PGⅠ/PGⅡ, and affected the abundance of gut microbiota such as Bacteroides and Ruminococcus in patients.Further analysis found that the regulation of the gut microbiota by CCFM1118-IB may promote the production of beneficial active metabolites, thereby improving the health of the host.However, CCFM1118-IB did not significantly affect the general serum biochemistry and other indicators, indicating that it does not affect the normal physiological status of the subjects.The results demonstrated that CCFM1118-IB has anti-H.pylori properties and diminish the harmful effects of H.pylori infection on human health.
[1] HOOI J K Y, LAI W Y, NG W K, et al.Global prevalence of Helicobacter pylori infection:Systematic review and meta-analysis[J].Gastroenterology, 2017, 153(2):420-429.
[2] QUAGLIA N C, DAMBROSIO A.Helicobacter pylori:A foodborne pathogen?[J].World Journal of Gastroenterology, 2018, 24(31):3472-3487.
[3] GONCIARZ W, WALENCKA M, MORAN A P, et al.Upregulation of MUC5AC production and deposition of LEWIS determinants by HELICOBACTER PYLORI facilitate gastric tissue colonization and the maintenance of infection[J].Journal of Biomedical Science, 2019, 26(1):23.
[4] LIANG B, YUAN Y, PENG X J, et al.Current and future perspectives for Helicobacter pylori treatment and management:From antibiotics to probiotics[J].Frontiers in Cellular and Infection Microbiology, 2022, 12:1042070.
[5] LIU L P, ZHAO Y X, FAN G R, et al.Helicobacter pylori infection enhances heparanase leading to cell proliferation via mitogen-activated protein kinase signalling in human gastric cancer cells[J].Molecular Medicine Reports, 2018, 18(6):5733-5741.
[6] FOCK K M, KATELARIS P, SUGANO K, et al.Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection[J].Journal of Gastroenterology and Hepatology, 2009, 24(10):1587-1600.
[7] QURESHI N, LI P, GU Q.Probiotic therapy in Helicobacter pylori infection:A potential strategy against a serious pathogen?[J].Applied Microbiology and Biotechnology, 2019, 103(4):1573-1588.
[8] MARCO M L, SANDERS M E, GÄNZLE M, et al.The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods[J].Nature Reviews Gastroenterology & Hepatology, 2021, 18:196-208.
[9] ŻÓŁKIEWICZ J, MARZEC A, RUSZCZYŃSKI M, et al.Postbiotics-a step beyond pre- and probiotics[J].Nutrients, 2020, 12(8):2189.
[10] HU J F, TIAN X Q, WEI T, et al.Anti- Helicobacter pylori activity of a Lactobacillus sp.PW-7 exopolysaccharide[J].Foods, 2021, 10(10):2453.
[11] DORON S, SNYDMAN D R.Risk and safety of probiotics[J].Clinical Infectious Diseases:an Official Publication of the Infectious Diseases Society of America, 2015, 60(Suppl 2):S129-S134.
[12] WANG S M, ZHANG M Y, YU L L, et al.Evaluation of the potential protective effects of Lactobacillus strains against Helicobacter pylori infection:A randomized, double-blinded, placebo-controlled trial[J].The Canadian Journal of Infectious Diseases & Medical Microbiology=Journal Canadien Des Maladies Infectieuses et De La Microbiologie Medicale, 2022, 2022:6432750.
[13] HOLZ C, BUSJAHN A, MEHLING H, et al.Significant reduction in Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648:A pilot study[J].Probiotics and Antimicrobial Proteins, 2015, 7(2):91-100.
[14] 张美怡, 翟齐啸, 赵建新, 等.鼠李糖乳杆菌JS-SZ-2-1抗幽门螺杆菌感染的临床效果评价[J].食品与发酵工业, 2020, 46(23):29-34.
ZHANG M Y, ZHAI Q X, ZHAO J X, et al.Clinical efficacy evaluation of Lactobacillus rhamnosus JS-SZ-2-1 against Helicobacter pylori infection[J].Food and Fermentation Industries, 2020, 46(23):29-34.
[15] 张华月. 具有幽门螺杆菌共聚集能力乳杆菌的筛选及临床功效评价[D].无锡:江南大学, 2022.
ZHANG H Y.Screening and clinical functional evaluation of Lactobacillus with co-aggregation ability of Helicobacter pylori[D].Wuxi:Jiangnan University, 2022.
[16] MEHLING H, BUSJAHN A.Non-viable Lactobacillus reuteri DSMZ 17648 (PylopassTM) as a new approach to Helicobacter pylori control in humans[J].Nutrients, 2013, 5(8):3062-3073.
[17] SUEZ J, ZMORA N, SEGAL E, et al.The pros, cons, and many unknowns of probiotics[J].Nature Medicine, 2019, 25(5):716-729.
[18] HOMAN M.Are probiotics useful in Helicobacter pylori eradication?[J].World Journal of Gastroenterology, 2015, 21(37):10644.
[19] 李露露, 王钧豪, 叶亚明, 等.乳杆菌与幽门螺杆菌共聚集的特性研究[J].食品与发酵工业, 2022, 48(21):1-8.
LI L L, WANG J H, YE Y M, et al.Characterization of Lactobacillus co-aggregation with Helicobacter pylori[J].Food and Fermentation Industries, 2022, 48(21):1-8.
[20] EKMEKCI H, ASLIM B, OZTURK S.Characterization of vaginal lactobacilli coaggregation ability with Escherichia coli[J].Microbiology and Immunology, 2009, 53(2):59-65.
[21] JI J F, YANG H.Using probiotics as supplementation for Helicobacter pylori antibiotic therapy[J].International Journal of Molecular Sciences, 2020, 21(3):1136.
[22] ZHANG S Y, SHI D, LI M R, et al.The relationship between gastric microbiota and gastric disease[J].Scandinavian Journal of Gastroenterology, 2019, 54(4):391-396.
[23] GUO Y, ZHANG Y, GERHARD M, et al.Effect of Helicobacter pylori on gastrointestinal microbiota:A population-based study in Linqu, a high-risk area of gastric cancer[J].Gut, 2020, 69(9):1598-1607.
[24] DU L J, CHEN B R, CHENG F L, et al.Effects of Helicobacter pylori therapy on gut microbiota:A systematic review and meta-analysis[J].Digestive Diseases, 2024, 42(1):102-112.
[25] FROST F, KACPROWSKI T, RÜHLEMANN M, et al.Helicobacter pylori infection associates with fecal microbiota composition and diversity[J].Scientific Reports, 2019, 9(1):20100.
